|
Tempest Therapeutics, Inc. (TPST) DCF Avaliação
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Tempest Therapeutics, Inc. (TPST) Bundle
Aprimore suas estratégias de investimento com a calculadora DCF da Tempest Therapeutics! Explore as finanças genuínas da Tempest, ajustam as projeções e despesas de crescimento e observe instantaneamente como essas modificações afetam o valor intrínseco de Tempest Therapeutics, Inc. (TPST).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -43.5 | -18.4 | -25.7 | -32.3 | -28.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 1.1 | .8 | 1.3 | 1.8 | .4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -44.6 | -19.2 | -27.0 | -34.1 | -29.2 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 63.5 | 18.8 | 51.8 | 31.2 | 39.2 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.3 | .3 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .7 | 1.6 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.5 | 1.1 | 1.0 | 1.1 | .8 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.4 | -.1 | -.1 | -.6 | -.2 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -44.6 | -19.1 | -28.2 | -35.1 | -29.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -43.7 | -18.4 | -27.8 | -32.2 | -29.2 | -.8 | .0 | .0 | .0 | .0 |
| WACC, % | 6.25 | 6.22 | 6.25 | 6.25 | 6.25 | 6.24 | 6.24 | 6.24 | 6.24 | 6.24 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -19 | |||||||||
| Equity Value | 18 | |||||||||
| Diluted Shares Outstanding, MM | 15 | |||||||||
| Equity Value Per Share | 1.15 |
What You Will Get
- Genuine Tempest Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Tempest Therapeutics, Inc. (TPST).
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates easily.
- Immediate Valuation Adjustments: Automatic recalculations to assess the effects of changes on Tempest Therapeutics’ fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analyses, and in-depth forecasts.
- Efficient and Precise: Avoid building models from the ground up while ensuring accuracy and adaptability.
Key Features
- Comprehensive TPST Data: Pre-filled with Tempest Therapeutics’ historical performance metrics and future projections.
- Fully Customizable Inputs: Modify revenue growth rates, profit margins, discount rates, tax assumptions, and capital investments.
- Dynamic Valuation Model: Instant updates to Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Testing: Develop various forecast scenarios to explore different valuation possibilities.
- User-Friendly Interface: Intuitive, organized, and crafted for both seasoned professionals and newcomers.
How It Works
- Step 1: Download the prebuilt Excel template featuring Tempest Therapeutics, Inc. (TPST) data included.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Tempest Therapeutics, Inc. (TPST) intrinsic value.
- Step 5: Make informed investment decisions or create reports utilizing the outputs.
Why Choose This Calculator for Tempest Therapeutics, Inc. (TPST)?
- Accurate Data: Up-to-date financials from Tempest Therapeutics ensure dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you from starting from square one.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Simple design and clear instructions make it accessible for all users.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for analyzing investments in biotech.
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for Tempest Therapeutics, Inc. (TPST) to clients.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insight into how biotech companies like Tempest Therapeutics, Inc. (TPST) are valued in the market.
What the Template Contains
- Preloaded TPST Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.